



# Medicine Supply Notification

MSN/2020/037

Lacosamide (Vimpat®) 50mg tablets (UCB Pharma Ltd)

Tier 2 – medium impact\*

Date of issue: 25/06/2020

## Summary

- Vimpat® 50mg tablets will be out of stock from early July until week commencing 20<sup>th</sup> July 2020.
- Vimpat® 10mg/ml syrup remains available.

## Actions Required

Where the patient has insufficient supplies to last until the resupply date:

- clinicians should consider prescribing Vimpat® (lacosamide) 10mg/ml syrup which is able to support the market during this time, ensuring that the patient is not intolerant to any of the excipients and is counselled on the appropriate dose and volume required (see supporting information below).
- if the above option is not considered appropriate, advice should be sought from specialists on management options.

## Supporting Information

- Vimpat® tablets and syrup are bioequivalent. Further information can be found in the SPC: <https://www.medicines.org.uk/emc/product/2285/smpc>
- Vimpat® syrup contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine. Sorbitol may cause gastrointestinal discomfort and a mild laxative effect. The syrup also contains aspartame (E951), a source of phenylalanine, which may be harmful for people with phenylketonuria.

## Enquiries

If you have any queries, please contact [DHSCmedicinesupplyteam@dhsc.gov.uk](mailto:DHSCmedicinesupplyteam@dhsc.gov.uk)